An Open-Label, Multi-Centre, Uncontrolled, Exploratory Trial Investigating Degarelix One-Month Dosing Regimen as Second-Line Hormonal Treatment After PSA-Failure in GnRH Agonist Treated Patients With Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2013
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Jan 2013 New source identified and integrated (German Clinical Trials Register; DRKS00004153).
- 16 Jul 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.